Selection of some of the most relevant articles by VHIO researchers published in 2017

Below is a selected list of articles published by VHIO researchers in 2017 with respective Impact Factors indicated.

First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. Carbone DP; Reck M; Paz-Ares L; Creelan B; Horn L; Steins M; Felip E; van den Heuvel MM; Ciuleanu TE; Badin F; Ready N; Hiltermann TJN; Nair S; Juergens R; Peters S; Minenza E; Wrangle JM; Rodriguez-Abreu D; Borghaei H; Blumenschein GR; Villaruz LC; Havel L; Krejci J; Corral Jaime J; Chang H; Geese WJ; Bhagavatheeswaran P; Chen AC; Socinski MA; CheckMate 026 Investigators. 2017. N Engl J Med. 376: 2415-2426. IF: 72,406

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T; ALEX Trial Investigators. 2017. N Engl J Med. 377: 829-838. IF: 72,406

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Tewari KS; Sill MW; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; DiSaia PJ; Copeland LJ; Creasman WT; Stehman FB; Brady MF; Burger RA; Thigpen JT; Birrer MJ; Waggoner SE; Moore DH; Look KY; Koh WJ; Monk BJ. 2017. Lancet. 390: 1654-1663. IF: 47,831

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O’Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA; ARIEL3 investigators. 2017. Lancet. 390: 1949-1961. IF: 47,831

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Zabala-Letona A; Arruabarrena-Aristorena A; Martín-Martín N; Fernandez-Ruiz S; Sutherland JD; Clasquin M; Tomas-Cortazar J; Jimenez J; Torres I; Quang P; Ximenez-Embun P; Bago R; Ugalde-Olano A; Loizaga-Iriarte A; Lacasa-Viscasillas I; Unda M; Torrano V; Cabrera D; van Liempd SM; Cendon Y; Castro E; Murray S; Revandkar A; Alimonti A; Zhang Y; Barnett A; Lein G; Pirman D; Cortazar AR; Arreal L; Prudkin L; Astobiza I; Valcarcel-Jimenez L; Zuñiga-García P; Fernandez-Dominguez I; Piva M; Caro-Maldonado A; Sánchez-Mosquera P; Castillo-Martín M; Serra V; Beraza N; Gentilella A; Thomas G; Azkargorta M; Elortza F; Farràs R; Olmos D; Efeyan A; Anguita J; Muñoz J; Falcón-Pérez JM; Barrio R; Macarulla T; Mato JM; Martinez-Chantar ML; Cordon-Cardo C; Aransay AM; Marks K; Baselga J; Tabernero J; Nuciforo P; Manning BD; Marjon K; Carracedo A. 2017. Nature. 547: 109-0. IF: 40,137

CANCER: A precision approach to tumour treatment. Dienstmann R; Tabernero J. 2017. Nature. 548: 40-41. IF: 40,137

CANCER: Division hierarchy leads to cell heterogeneity. Seoane J. 2017. Nature. 549: 164-166. IF: 40,137

Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Bullman S; Pedamallu CS; Sicinska E; Clancy TE; Zhang X; Cai D; Neuberg D; Huang K; Guevara F; Nelson T; Chipashvili O; Hagan T; Walker M; Ramachandran A; Diosdado B; Serna G; Mulet N; Landolfi S; Ramon Y Cajal S; Fasani R; Aguirre AJ; Ng K; Élez E; Ogino S; Tabernero J; Fuchs CS; Hahn WC; Nuciforo P; Meyerson M. 2017. Science. 358: 1443-0. IF: 37,205

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Dienstmann R; Vermeulen L; Guinney J; Kopetz S; Tejpar S; Tabernero J. 2017. Nat Rev Cancer. 17: 79-92. IF: 37,147

Interrogating open issues in cancer precision medicine with patient-derived xenografts. Byrne AT; Alférez DG; Amant F; Annibali D; Arribas J; Biankin AV; Bruna A; Budinská E; Caldas C; Chang DK; Clarke RB; Clevers H; Coukos G; Dangles-Marie V; Eckhardt SG; Gonzalez-Suarez E; Hermans E; Hidalgo M; Jarzabek MA; de Jong S; Jonkers J; Kemper K; Lanfrancone L; Mælandsmo GM; Marangoni E; Marine JC; Medico E; Norum JH; Palmer HG; Peeper DS; Pelicci PG; Piris-Gimenez A; Roman-Roman S; Rueda OM; Seoane J; Serra V; Soucek L; Vanhecke D; Villanueva A; Vinolo E; Bertotti A; Trusolino L. 2017. Nat Rev Cancer. 17: 254-268. IF: 37,147

Drugging the ‘undruggable’ cancer targets. Dang CV; Reddy EP; Shokat KM; Soucek L. 2017. Nat Rev Cancer. 17: 502-508. IF: 37,147

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O’Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA. 2017. Lancet Oncol. 18: 75-87. IF: 33,900

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A. 2017. Lancet Oncol. 18: 545-554. IF: 33,900

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; Del Alba AG; Castellano D; Gallardo E; Anido U; Del Muro XG; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J. 2017. Lancet Oncol. 18: 672-681. IF: 33,900

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiello-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M. 2017. Lancet Oncol. 18: 904-916. IF: 33,900

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E. 2017. Lancet Oncol. 18: 874-886. IF: 33,900

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J; LOTUS investigators. 2017. Lancet Oncol. 18: 1360-1372. IF: 33,900

The Cancer Moonshot from a European perspective. Ciardiello F; Tabernero J. 2017. Lancet Oncol. 18: 626-0. IF: 33,900

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ. 2017. Lancet Oncol. 18: 1590-1599. IF: 33,900

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Griffith M; Spies NC; Krysiak K; McMichael JF; Coffman AC; Danos AM; Ainscough BJ; Ramirez CA; Rieke DT; Kujan L; Barnell EK; Wagner AH; Skidmore ZL; Wollam A; Liu CJ; Jones MR; Bilski RL; Lesurf R; Feng YY; Shah NM; Bonakdar M; Trani L; Matlock M; Ramu A; Campbell KM; Spies GC; Graubert AP; Gangavarapu K; Eldred JM; Larson DE; Walker JR; Good BM; Wu C; Su AI; Dienstmann R; Margolin AA; Tamborero D; Lopez-Bigas N; Jones SJ; Bose R; Spencer DH; Wartman LD; Wilson RK; Mardis ER; Griffith OL. 2017. Nat Genet. 49: 170-174. IF: 27,959

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Phelan CM; Kuchenbaecker KB; Tyrer JP; Kar SP; Lawrenson K; Winham SJ; Dennis J; Pirie A; Riggan MJ; Chornokur G; Earp MA; Lyra PC; Lee JM; Coetzee S; Beesley J; McGuffog L; Soucy P; Dicks E; Lee A; Barrowdale D; Lecarpentier J; Leslie G; Aalfs CM; Aben KKH; Adams M; Adlard J; Andrulis IL; Anton-Culver H; Antonenkova N; AOCS study group; Aravantinos G; Arnold N; Arun BK; Arver B; Azzollini J; Balmaña J; Banerjee SN; Barjhoux L; Barkardottir RB; Bean Y; Beckmann MW; Beeghly-Fadiel A; Benitez J; Bermisheva M; Bernardini MQ; Birrer MJ; Bjorge L; Black A; Blankstein K; Blok MJ; Bodelon C; Bogdanova N; Bojesen A; Bonanni B; Borg Å; Bradbury AR; Brenton JD; Brewer C; Brinton L; Broberg P; Brooks-Wilson A; Bruinsma F; Brunet J; Buecher B; Butzow R; Buys SS; Caldes T; Caligo MA; Campbell I; Cannioto R; Carney ME; Cescon T; Chan SB; Chang-Claude J; Chanock S; Chen XQ; Chiew YE; Chiquette J; Chung WK; Claes KBM; Conner T; Cook LS; Cook J; Cramer DW; Cunningham JM; D’Aloisio AA; Daly MB; Damiola F; Damirovna SD; Dansonka-Mieszkowska A; Dao F; Davidson R; DeFazio A; Delnatte C; Doheny KF; Diez O; Ding YC; Doherty JA; Domchek SM; Dorfling CM; Dörk T; Dossus L; Duran M; Dürst M; Dworniczak B; Eccles D; Edwards T; Eeles R; Eilber U; Ejlertsen B; Ekici AB; Ellis S; Elvira M; EMBRACE Study; et al. 2017. Nat Genet. 49: 680-691. IF: 27,959

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Milne RL; Kuchenbaecker KB; Michailidou K; Beesley J; Kar S; Lindström S; Hui S; Lemaçon A; Soucy P; Dennis J; Jiang X; Rostamianfar A; Finucane H; Bolla MK; McGuffog L; Wang Q; Aalfs CM; ABCTB Investigators; Adams M; Adlard J; Agata S; Ahmed S; Ahsan H; Aittomäki K; Al-Ejeh F; Allen J; Ambrosone CB; Amos CI; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Auber B; Auer PL; Ausems MGEM; Azzollini J; Bacot F; Balmaña J; Barile M; Barjhoux L; Barkardottir RB; Barrdahl M; Barnes D; Barrowdale D; Baynes C; Beckmann MW; Benitez J; Bermisheva M; Bernstein L; Bignon YJ; Blazer KR; Blok MJ; Blomqvist C; Blot W; Bobolis K; Boeckx B; Bogdanova NV; Bojesen A; Bojesen SE; Bonanni B; Børresen-Dale AL; Bozsik A; Bradbury AR; Brand JS; Brauch H; Brenner H; Bressac-de Paillerets B; Brewer C; Brinton L; Broberg P; Brooks-Wilson A; Brunet J; Brüning T; Burwinkel B; Buys SS; Byun J; Cai Q; Caldés T; Caligo MA; Campbell I; Canzian F; Caron O; Carracedo A; Carter BD; Castelao JE; Castera L; Caux-Moncoutier V; Chan SB; Chang-Claude J; Chanock SJ; Chen X; Cheng TD; Chiquette J; Christiansen H; Claes KBM; Clarke CL; Conner T; Conroy DM; Cook J; Cordina-Duverger E; Cornelissen S; Coupier I; Cox A; Cox DG; Cross SS; Cuk K; Cunningham JM; Czene K; Daly MB; Damiola F; Darabi H; Davidson R; De Leeneer K; Devilee P; Dicks E; Diez O; Ding YC; Ditsch N; Doheny KF; Domchek SM; Dorfling CM; Dörk T; Dos-Santos-Silva I; Dubois S; Dugué PA; Dumont M; Dunning AM; Durcan L; Dwek M; Dworniczak B; Eccles D; Eeles R; Ehrencrona H; Eilber U; Ejlertsen B; Ekici AB; Eliassen AH; EMBRACE; et al. 2017. Nat Genet. 49: 1767-1778. IF: 27,959

Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study. Ott PA; Elez E; Hiret S; Kim DW; Morosky A; Saraf S; Piperdi B; Mehnert JM. 2017. J Clin Oncol. 35: 3823-3829. IF: 24,008

Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry. Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou, N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A. 2017. J Clin Oncol. 35: 1403-1410. IF: 24,008

Pertuzumab Use in the Adjuvant Setting: Why Not? Prat A. 2017. J Clin Oncol. 35: 1138-0. IF: 24,008

Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Balmaña J; Nathanson K; Offit K; Robson M; Domchek S. 2017. J Clin Oncol. 35: 1262-1263. IF: 24,008

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Yang JC; Ahn MJ; Kim DW; Ramalingam SS; Sequist LV; Su WC; Kim SW; Kim JH; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin CC; Mann H; Cantarini M; Ghiorghiu S; Jänne PA. 2017. J Clin Oncol. 35: 1288-0. IF: 24,008

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. Scott DW; Abrisqueta P; Wright GW; Slack GW; Mottok A; Villa D; Jares P; Rauert-Wunderlich H; Royo C; Clot G; Pinyol M; Boyle M; Chan FC; Braziel RM; Chan WC; Weisenburger DD; Cook JR; Greiner TC; Fu K; Ott G; Delabie J; Smeland EB; Holte H; Jaffe ES; Steidl C; Connors JM; Gascoyne RD; Rosenwald A; Staudt LM; Campo E; Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project. 2017. J Clin Oncol. 35: 1668-1677. IF: 24,008

Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. Lecarpentier J; Silvestri V; Kuchenbaecker KB; Barrowdale D; Dennis J; McGuffog L; Soucy P; Leslie G; Rizzolo P; Navazio AS; Valentini V; Zelli V; Lee A; Amin Al Olama A; Tyrer JP; Southey M; John EM; Conner TA; Goldgar DE; Buys SS; Janavicius R; Steele L; Ding YC; Neuhausen SL; Hansen TVO; Osorio A; Weitzel JN; Toss A; Medici V; Cortesi L; Zanna I; Palli D; Radice P; Manoukian S; Peissel B; Azzollini J; Viel A; Cini G; Damante G; Tommasi S; Peterlongo P; Fostira F; Hamann U; Evans DG; Henderson A; Brewer C; Eccles D; Cook J; Ong KR; Walker L; Side LE; Porteous ME; Davidson R; Hodgson S; Frost D; Adlard J; Izatt L; Eeles R; Ellis S; Tischkowitz M; EMBRACE; Godwin AK; Meindl A; Gehrig A; Dworniczak B; Sutter C; Engel C; Niederacher D; Steinemann D; Hahnen E; Hauke J; Rhiem K; Kast K; Arnold N; Ditsch N; Wang-Gohrke S; Wappenschmidt B; Wand D; Lasset C; Stoppa-Lyonnet D; Belotti M; Damiola F; Barjhoux L; Mazoyer S; GEMO Study Collaborators; Van Heetvelde M; Poppe B; De Leeneer K; Claes KBM; de la Hoya M; Garcia-Barberan V; Caldes T; Perez Segura P; Kiiski JI; Aittomäki K; Khan S; Nevanlinna H; van Asperen CJ; HEBON; Vaszko T; Kasler M; Olah E; Balmaña J; Gutiérrez-Enríquez S; Diez O; Teulé A; Izquierdo A; Darder E; Brunet J; et al. 2017. J Clin Oncol. 35: 2240-2250. IF: 24,008

Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study. Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC. 2017. J Clin Oncol. 35: 2535-2541. IF: 24,008

HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2–positive metastatic gastric or gastroesophageal junction adenocarcinoma. Shah MA; Xu RH; Bang YJ; Hoff PM; Liu T; Herráez-Baranda LA; Xia F; Garg A; Shing M; Tabernero J. 2017. J Clin Oncol. 35: 2558-2567. IF: 24,008

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E. 2017. J Clin Oncol. 35: 2781-0. IF: 24,008

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; SOFT; TEXT Investigators; International Breast Cancer Study Group. 2017. J Clin Oncol. 35: 3113-0. IF: 24,008

Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer - PROSELICA. Eisenberger M; Hardy-Bessard AC; Kim CS; Géczi L; Ford D; Mourey L; Carles J; Parente P; Font A; Kacso G; Chadjaa M; Zhang W; Bernard J; de Bono J. 2017. J Clin Oncol. 35: 3198-3206. IF: 24,008

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. Vitolo U; Trnený M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH. 2017. J Clin Oncol. 35: 3529-3537. IF: 24,008

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE. 2017. J Clin Oncol. 35: 3924-0. IF: 24,008

Targeting c-MET in gastrointestinal tumours: Rationale, opportunities and challenges. Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S; MErCuRIC consortium. 2017. Nat Rev Clin Oncol. 14: 562-576. IF: 20,693

A first-in-human phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates Robust and safe targeting of AKT in patients with solid tumors. Saura C; Roda D; Roselló S; Oliveira M; Macarulla T; Pérez-Fidalgo JA; Morales-Barrera R; Sanchis-García JM; Musib L; Budha N; Zhu J; Nannini M; Chan WY; Sanabria Bohórquez SM; Meng RD; Lin K; Yan Y; Patel P; Baselga J; Tabernero J; Cervantes A. 2017. Cancer Discov. 7: 102-113. IF: 20,011

A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. van Geel RM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema M; Faris JE; Eskens FA; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JH. 2017. Cancer Discov. 7: 610-619. IF: 20,011

Improving the armamentarium of PI3K inhibitors with isoform-selective agents: A new light in the darkness. Rodon J; Tabernero J. 2017. Cancer Discov. 7: 666-669. IF: 20,011

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA; BELIEF collaborative group. 2017. Lancet Respir Med. 5: 435-444. IF: 19,287

Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Egoavil C; Juarez M; Guarinos C; Rodríguez-Soler M; Hernández-Illán E; Alenda C; Payá A; Castillejo A; Serradesanferm A; Bujanda L; Fernández-Bañares F; Cubiella J; de-Castro L; Guerra A; Aguirre E; Herreros-de-Tejada A; Bessa X; Herráiz M; Marín-Gabriel JC; Balmaña J; Piñol V; Cuatrecasas M; Balaguer F; Castells A; Soto JL; Zapater P; Jover R. 2017. Gastroenterology. 153: 106-1122. IF: 18,392

Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: A post hoc analysis of the Mainsail study. de Morrée ES; Vogelzang NJ; Petrylak DP; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; Ochoa de Olza M; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; Li JS; de Wit R. 2017. JAMA Oncol. 3: 68-75. IF: 16,559

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. Fumagalli, Debora; Venet, David; Ignatiadis, Michail; Azim, Jr., Hatem A.; Maetens, Marion; Rothe, Francoise; Salgado, Roberto; Bradbury, Ian; Pusztai, Lajos; Harbeck, Nadia; Gomez, Henry; Chang, Tsai-Wang; Coccia-Portugal, Maria Antonia; Di Cosimo, Serena; de Azambuja, Evandro; de la Pena, Lorena; Nuciforo, Paolo; Brase, Jan C.; Huober, Jens; Baselga, Jose; Piccart, Martine; Loi, Sherene; Sotiriou, Christos. 2017. JAMA Oncol. 3: 227-234. IF: 16,559

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. Tejpar, Sabine; Stintzing, Sebastian; Ciardiello, Fortunato; Tabernero, Josep; Van Cutsem, Eric; Beier, Frank; Esser, Regina; Lenz, Heinz-Josef; Heinemann, Volker. 2017. JAMA Oncol. 3: 194-201. IF:16,559

Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric randomized clinical trial. Shah MA; Bang YJ; Lordick F; Alsina M; Chen M; Hack SP; Bruey JM; Smith D; McCaffery I; Shames DS; Phan S; Cunningham D. 2017. JAMA Oncol. 3: 620-627. IF: 16,559

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L; RISC Investigators. 2017. Eur Urol. 71: 281-289. IF: 16,265

Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients. Gonzalez-Billalabeitia E; Castellano D; Sobrevilla N; Guma J; Hervas D; Luengo MI; Aparicio J; Sanchez-Muñoz A; Mellado B; Saenz A; Valverde C; Fernandez A; Margeli M; Duran I; Fernandez S; Sastre J; Ros S; Maroto P; Manneh R; Cerezuela P; Carmona-Bayonas A; Spanish Germ Cell Cancer Group/Grupo Germinal (SGCCG). 2017. J Natl Cancer Inst. IF: 12,589

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. Taieb J; Le Malicot K; Shi Q; Penault Lorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Francois Emile J; Laurent Puig P; Sinicrope FA. 2017. J Natl Cancer Inst. IF: 12,589

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC; Lush M; Hamann U; Southey M; John EM; Chung WK; Daly MB; Buys SS; Goldgar DE; Dorfling CM; van Rensburg EJ; Chun Ding Y; Ejlertsen B; Gerdes AM; Hansen TV; Slager S; Hallberg E; Benitez J; Osorio A; Cohen N; Lawler W; Weitzel JN; Peterlongo P; Pensotti V; Dolcetti R; Barile M; Bonanni B; Azzollini J; Manoukian S; Peissel B; Radice P; Savarese A; Papi L; Giannini G; Fostira F; Konstantopoulou I; Adlard J; Brewer C; Cook J; Davidson R; Eccles D; Eeles R; Ellis S; Frost D; Hodgson S; Izatt L; Lalloo F; Ong KR; Godwin AK; Arnold N; Dworniczak B; Engel C; Gehrig A; Hahnen E; Hauke J; Kast K; Meindl A; Niederacher D; Schmutzler RK; Varon-Mateeva R; Wang-Gohrke S; Wappenschmidt B; Barjhoux L; Collonge-Rame MA; Elan C; Golmard L; GEMO Study Collaborators; EMBRACE; Barouk-Simonet E; Lesueur F; Mazoyer S; Sokolowska J; Stoppa-Lyonnet D; Isaacs C; Claes KBM; Poppe B; de la Hoya M; Garcia-Barberan V; Aittomaki K; Nevanlinna H; Ausems MGEM; de Lange JL; Gomez Garcia EB; Hogervorst FB; HEBON; Kets CM; Meijers-Heijboer HE; Oosterwijk JC; Rookus MA; van Asperen CJ; van den Ouweland AMW; van Doorn HC; van Os TAM; Kwong A; Olah E; Diez O; Brunet J; et al. 2017. J Natl Cancer Inst. IF: 12,589

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Jacobsen K; Bertran-Alamillo J; Molina MA; Teixidó C; Karachaliou N; Pedersen MH; Castellví J; Garzón M; Codony-Servat C; Codony-Servat J; Giménez-Capitán A; Drozdowskyj A; Viteri S; Larsen MR; Lassen U; Felip E; Bivona TG; Ditzel HJ; Rosell R. 2017. Nat Commun. 8: 410-0. IF: 12,124

Modulation of telomere protection by the PI3K/AKT pathway. Méndez-Pertuz M; Martínez P; Blanco-Aparicio C; Gómez-Casero E; Belen García A; Martínez-Torrecuadrada J; Palafox M; Cortés J; Serra V; Pastor J; Blasco MA. 2017. Nat Commun. 8: 1278-0. IF: 12,124

Single-cell transcriptome conservation in cryopreserved cells and tissues. Guillaumet-Adkins A; Rodríguez-Esteban G; Mereu E; Mendez-Lago M; Jaitin DA; Villanueva A; Vidal A; Martinez-Marti A; Felip E; Vivancos A; Keren-Shaul H; Heath S; Gut M; Amit I; Gut I; Heyn H. 2017. Genome Biol. 18: 45-0. IF: 11,908

An update on the management of sporadic desmoid-type fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Kasper, B.; Baumgarten, C.; Garcia, J.; Bonvalot, S.; Haas, R.; Haller, F.; Hohenberger, P.; Penel, N.; Messiou, C.; van der Graaf, W.T.; Gronchi, A.; Bauer, S.; Blay, J.Y.; van Coevorden, F.; Dileo, P.; Dürr, H.R.; Fiore, M.; Grünwald, V.; Jones, R.; Judson, I.; Kettelhack, C.; Kopeckova, K.; Lazar, A.; Lindner, L.H.; Martin-Broto, J.; Rutkowski, P.; Stacchiotti, S.; Stoeckle, E.; Valverde, C.; Verhoef, K.; Wardelmann, E.; Wartenberg, M. 2017. Ann Oncol. 28: 2399-2408. IF: 11,855

Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency. Remon, J.; Soria, J.C. 2017. Ann Oncol. 28: 196-198. IF: 11,855

Research needs in breast cancer. Cardoso F; Harbeck N; Barrios CH; Bergh J; Cortés J; El Saghir N; Francis PA; Hudis CA; Ohno S; Partridge AH; Sledge GW; Smith IE; Gelmon KA. 2017. Ann Oncol. 28: 208-217. IF: 11,855

Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: Do we need to worry? Font R; Espinas JA; Layos L; Martinez Villacampa M; Capdevila J; Tobeña M; Pisa A; Pericay C; Lezcano C; Fort E; Cardona I; Berga N; Solà J; Borras JM. 2017. Ann Oncol. 28: 831-835. IF: 11,855

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Remon, J.; Caramella, C.; Jovelet, C.; Lacroix, L.; Lawson, A.; Smalley, S.; Howarth, K.; Gale, D.; Green, E.; Plagnol, V.; Rosenfeld, N.; Planchard, D.; Bluthgen, M.V.; Gazzah, A.; Pannet, C.; Nicotra, C.; Auclin, E.; Soria, J.C.; Besse, B. 2017. Ann Oncol. 28: 784-790. IF: 11,855

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Shi W; Jiang T; Nuciforo P; Hatzis C; Holmes E; Harbeck N; Sotiriou C; Peña L; Loi S; Rosa DD; Chia S; Wardley A; Ueno T; Rossari J; Eidtmann H; Armour A; Piccart-Gebhart M; Rimm DL; Baselga J; Pusztai L. 2017. Ann Oncol. 28: 128-135. IF: 11,855

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Swain SM; Schneeweiss A; Gianni L; Gao JJ; Stein A; Waldron-Lynch M; Heeson S; Beattie MS; Yoo B; Cortes J; Baselga J. 2017. Ann Oncol. 28: 761-768. IF: 11,855

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial. Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA. 2017. Ann Oncol. 28: 874-881. IF: 11,855

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P; for PETACC8 investigators. 2017. Ann Oncol. 28: 824-830. IF: 11,855

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Dienstmann, R.; Mason, M. J.; Sinicrope, F. A.; Phipps, A. I.; Tejpar, S.; Nesbakken, A.; Danielsen, S. A.; Sveen, A.; Buchanan, D. D.; Clendenning, M.; Rosty, C.; Bot, B.; Alberts, S. R.; Jessup, J. Milburn; Lothe, R. A.; Delorenzi, M.; Newcomb, P. A.; Sargent, D.; Guinney, J. 2017. Ann Oncol. 28: 1023-1031. IF: 11,855

A step towards the harmonization of clinical trials inform consent forms. Remon J; Ferté C. 2017. Ann Oncol. 28: 910-912. IF: 11,855

Intratumoral heterogeneity in gastric cancer: a new challenge to face. Alsina M; Gullo I; Carneiro F. 2017. Ann Oncol. 28: 912-913. IF: 11,855

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC. 2017. Ann Oncol. 28: 1309-1315. IF: 11,855

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A. 2017. Ann Oncol. 28: 1294-1301. IF: 11,855

Targeting the fibroblast growth factor receptor 2 in gastric cancer: Promise or pitfall? Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J. 2017. Ann Oncol. 28: 1207-1216. IF: 11,855

The search for simplicity: Is this compatible with precision medicine? Nuciforo PG. 2017. Ann Oncol. 28: 10-12. IF: 11,855

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Poveda A; Del Campo JM; Ray-Coquard I; Alexandre J; Provansal M; Guerra Alía EM; Casado A; Gonzalez-Martin A; Fernández C; Rodriguez I; Soto A; Kahatt C; Fernández Teruel C; Galmarini CM; Pérez de la Haza A; Bohan P; Berton-Rigaud D. 2017. Ann Oncol. 28: 1280-1287. IF: 11,855

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F. 2017. Ann Oncol. 28: 1523-1531. IF: 11,855

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Bellmunt J; Kerst JM; Vázquez F; Morales-Barrera R; Grande E; Medina A; González Graguera MB; Rubio G; Anido U; Fernández Calvo O; González-Billalabeitia E; Van den Eertwegh AJM; Pujol E; Perez-Gracia JL; González Larriba JL; Collado R; Los M; Maciá S; De Wit R; SOGUG and DUOS. 2017. Ann Oncol. 28: 1517-1522. IF: 11,855

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Banerjee S; Califano R; Corral J; de Azambuja E; De Mattos-Arruda L; Guarneri V; Hutka M; Jordan K; Martinelli E; Mountzios G; Ozturk MA; Petrova M; Postel-Vinay S; Preusser M; Qvortrup C; Volkov MNM; Tabernero J; Olmos D; Strijbos MH. 2017. Ann Oncol. 28: 1590-1596. IF: 11,855

Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio. Cherny NI; Dafni U; Bogaerts J; Pentheroudakis G; Tabernero J; Zielinski C; de Vries EGE. 2017. Ann Oncol. 28: 2031-2032. IF: 11,855

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F. 2017. Ann Oncol. 28: 1713-1729. IF: 11,855

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies. Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M. 2017. Ann Oncol. 28: 1862-1868. IF: 11,855

An antisense oligonucleotide targeting TGF-ß2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. Huber-Ruano I; Raventós C; Cuartas I; Sánchez-Jaro C; Arias A; Parra JL; Wosikowski K; Janicot M; Seoane J. 2017. Ann Oncol. 28: 2278-2285. IF: 11,855

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer. Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F. 2017. Ann Oncol. 28: 2241-2247. IF: 11,855

Reply to the letter to the editor ‘Can we trust burnout research?’ by Bianchi et al. Banerjee S; Preusser M; Tabernero J; Strijbos M. 2017. Ann Oncol. 28: 2625-2626. IF: 11,855

ESMO-Magnitude of Clinical Benefit Scale version 1.1. Cherny NI; Dafni U; Bogaerts J; Latino NJ; Pentheroudakis G; Douillard JY; Tabernero J; Zielinski C; Piccart MJ; de Vries EGE. 2017. Ann Oncol. 28: 2340-2366. IF: 11,855

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A. 2017. Ann Oncol. 28: 2451-2457. IF: 11,855

Observation as the initial management strategy in patients with mantle cell lymphoma. Abrisqueta P; Scott DW; Slack GW; Steidl C; Mottok A; Gascoyne RD; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D. 2017. Ann Oncol. 28: 2489-2495. IF: 11,855

Reply to the letter to the editor `Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer’ by Sciallero et al. Dienstmann R; Guinney J. 2017. Ann Oncol. 28: 2889-2890. IF: 11,855

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Sanz-Garcia E; Argiles G; Elez E; Tabernero J. 2017. Ann Oncol. 28: 2648-2657. IF: 11,855

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Martin-Broto J; Redondo A; Valverde C; Vaz MA; Mora J; Garcia Del Muro X; Gutierrez A; Tous C; Carnero A; Marcilla D; Carranza A; Sancho P; Martinez-Trufero J; Diaz-Beveridge R; Cruz J; Encinas V; Taron M; Moura DS; Luna P; Hindi N; Lopez-Pousa A. 2017. Ann Oncol. 28: 2994-2999. IF: 11,855

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Arnold D; Fuchs C; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I. 2017. Ann Oncol. 28: 2932-2942. IF: 11,855

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. García-Foncillas J; Alba E; Aranda E; Díaz-Rubio E; López-López R; Tabernero J; Vivancos A. 2017. Ann Oncol. 28: 2943-2949. IF: 11,855

DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time? Páez D; Salazar R; Tabernero J. 2017. Ann Oncol. 28: 2913-2914. IF: 11,855

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤ 30% blasts. Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG. 2017. Leukemia. 31: 2799-2806. IF: 11,702

TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus. Senís E; Mockenhaupt S; Rupp D; Bauer T; Paramasivam N; Knapp B; Gronych J; Grosse S; Windisch MP; Schmidt F; Theis FJ; Eils R; Lichter P; Schlesner M; Bartenschlager R; Grimm D. 2017. Nucleic Acids Res. IF: 10,162

Histone H1 depletion triggers an interferon response in cancer cells via activation of heterochromatic repeats. Izquierdo-Bouldstridge A; Bustillos A; Bonet-Costa C; Aribau-Miralbés P; García-Gomis D; Dabad M; Esteve-Codina A; Pascual-Reguant L; Peiró S; Esteller M; Murtha M; Millán-Ariño L; Jordan A. 2017. Nucleic Acids Res. 45: 11622-11642. IF: 10,162.